ArticleClinical interventions in aging2019
Prediction of chemotherapy adverse reactions and mortality in older patients with primary lung cancer through frailty index based on routine laboratory data.
Article in Clinical interventions in aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Prevalence of Frailty and Its Predictors Among Patients With Cancer at the Chemotherapy Stage: Systematic Review.JMIR cancer · 2025Pooled it
- The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.Journal of medical screening · 2023Pooled it
- The frailty index based on laboratory test data as a tool to investigate the impact of frailty on health outcomes: a systematic review and meta-analysis.Age and ageing · 2023Pooled it
- Impacts of Frailty on Prognosis in Lung Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Comparison of Electronic Health Data-Based Frailty Assessment Tools for Prediction of Adverse Outcomes of Patients With Chronic Kidney Disease.Nephrology (Carlton, Vic.) · 2026Article
- Latent profiles of frailty in patients with head and neck cancer undergoing radiotherapy: a cross-sectional study.BMJ open · 2026Article
- Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Prevalence and predictors of frailty among older patients with lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Real-world performance of the machine learning-based prediction of chemotherapy-associated adverse effects in lung cancer.Oncology letters · 2026Article
- Association Between the Frailty Index Based on Laboratory Tests and All-Cause Mortality in Hospitalized Older Adults: Retrospective Cohort Study.JMIR aging · 2025Article
- Investigating Factors Related to Length of Hospital Stay in Male Patients With Lung Cancer Undergoing Chemotherapy.Cureus · 2025Article
- Association Between Preoperative Frailty Using Frailty Index-Laboratory Test and Clinical Outcomes in Older Adults Undergoing Brain Tumor Surgery.Nursing & health sciences · 2025Article
- The efficacy and safety of tislelizumab in the treatment of locally advanced or metastatic lung cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Review
- FI-Lab predicts all-cause mortality, but not successful rehabilitation, among patients aged 65 and older after hip or pelvic fracture.Frontiers in medicine · 2025Article
- Article
- Frailty and Cancer Prognosis.Current oncology reports · 2024Review
- Harnessing physical activity monitoring and digital biomarkers of frailty from pendant based wearables to predict chemotherapy resilience in veterans with cancer.Scientific reports · 2024Article
- How frail is frail in oncology studies? A scoping review.BMC cancer · 2023Article
- Prognostic significance of frailty in hospitalized elderly patients with community-acquired pneumonia: a retrospective cohort study.BMC geriatrics · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the role of a pre-chemotherapy frailty index based on routine laboratory data in predicting mortality and chemotherapy adverse reactions among older patients with primary lung cancer.
designRetrospective cohort study.
settingWest China Hospital, Chengdu, China.
participantsWe included patients aged ≥60 years with primary lung cancer receiving the first course of chemotherapy. MEASUREMENTS: Data were collected from medical records, local government death databases or telephone interviews. Outcomes included chemotherapy adverse reactions and all-cause mortality. We constructed a frailty index based on 44 laboratory variables (FI-LAB) before chemotherapy, and chose the following cutoff points: robust (0.0-0.2), pre-frail (0.2-0.35) and frail (≥0.35).
resultsWe included 1,020 patients (71.4% male; median age: 65 years old). Both pre-frailty and frailty was associated with any chemotherapy adverse reactions and infections during chemotherapy (OR=3.48, 95%CI: 1.77-6.87; OR=3.58, 95%CI: 1.55-8.26, respectively). Frail patients had a shorter median overall survival rate compared to robust patients (18.05 months vs 38.89 months, log-rank
conclusionsFrailty assessed by routine laboratory data indicates increased risks of chemotherapy adverse reactions and death in older patients with primary lung cancer receiving the first course of chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.